XNK Therapeutics is a clinical-stage immunotherapy company developing autologous NK cell-based products on a proprietary technology platform. Its lead investigational candidate is being evaluated in a Phase II study in multiple myeloma in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab). The company is also pursuing a proof-of-concept study in acute myeloid leukemia using patient samples from The University of Texas MD Anderson Cancer Center. XNK’s platform was developed to target cancers, including settings where allogeneic cell products are not readily applicable. The recent capital raise is intended primarily to finance clinical development in multiple myeloma and other indications. XNK is headquartered in Stockholm, Sweden and emphasizes commercialisation and global growth of its product portfolio.

Total raised

$14M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2022